Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
Pharmaceutical Insights: Baloxavir Marboxil's R&D Progress and its Mechanism of Action on Drug Target
30 October 2023
This article summarized the latest R&D progress of Baloxavir Marboxil, the Mechanism of Action for Baloxavir Marboxil, and the drug target R&D trends for Baloxavir Marboxil.
Bio Sequence
3 min read
The Evolution of Competitive Landscape Behind the Best Pharmaceutical Agent Tirzepatide in 2023
30 October 2023
Exploring the changes occurring within the application structure amongst Tirzepatide's top 10 patent assignees over time delivers insights into the competitive landscape's evolution.
Drug Insights
4 min read
Betamethasone Sodium Phosphate: Detailed Review of its Transformative R&D Success
27 October 2023
This article summarized the latest R&D progress of Betamethasone Sodium Phosphate, the mechanism of action for Betamethasone Sodium Phosphate, and the drug target R&D trends for Betamethasone Sodium Phosphate.
Latest Hotspot
3 min read
Anshi Biotechnology's small molecule selective MET inhibitor, Bozitinib, has applied for marketing for a new indication, the treatment of gliomatosis cerebri
27 October 2023
On Oct 24, 2023, China's CDE announced that Purunao Biotechnology, a subsidiary of Anshi Biotechnology, applied to list a new indication for the Class 1 new drug Vebreltinib on their official website.
Drug Insights
5 min read
Pharmaceutical Insights: toremifene citrate's R&D Progress and its Mechanism of Action on Drug Target
27 October 2023
This article summarized the latest R&D progress of toremifene citrate, the Mechanism of Action for toremifene citrate, and the drug target R&D trends for toremifene citrate.
Bio Sequence
3 min read
Contemporary Competitive Scenario: Analyzing Roche's Emergent Product, Trontinemab
27 October 2023
Exploring the changes occurring within the application structure amongst Trontinemab's top 10 patent assignees over time delivers insights into the competitive landscape's evolution.
Drug Insights
5 min read
Exploring treosulfan's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
27 October 2023
This article summarized the latest R&D progress of treosulfan, the Mechanism of Action for treosulfan, and the drug target R&D trends for treosulfan.
Latest Hotspot
3 min read
The marketing application for Huadong Medicine's FRα ADC Mirvetuximab Soravtansine Injection has been accepted
27 October 2023
On Oct 25, 2023, Huadong Medicine's subsidiary, Hangzhou Zhongmeihuadong Pharmaceutical, was granted a "Notice of Acceptance" by the NMPA for their marketing application for Mirvetuximab Soravtansine Injection (IMGN853, HDM2002), co-developed with ImmunoGen.
Drug Insights
4 min read
Decoding trihexyphenidyl hydrochloride: A Comprehensive Study of its R&D Trends
27 October 2023
This article summarized the latest R&D progress of trihexyphenidyl hydrochloride, the Mechanism of Action for trihexyphenidyl hydrochloride, and the drug target R&D trends for trihexyphenidyl hydrochloride.
Bio Sequence
2 min read
Biological Glossary | What are Complementarity-determining regions (CDRs)?
27 October 2023
Complementarity-determining regions (CDRs) are essential components of the variable chains found in immunoglobulins (antibodies) and T cell receptors.
Drug Insights
4 min read
Deep Scientific Insights on trimetazidine hydrochloride's R&D Progress
27 October 2023
This article summarized the latest R&D progress of trimetazidine hydrochloride, the Mechanism of Action for trimetazidine hydrochloride, and the drug target R&D trends for trimetazidine hydrochloride.
Latest Hotspot
3 min read
Celltrion's Infliximab (subcutaneous formulation) receives FDA approval for the treatment of inflammatory bowel disease
27 October 2023
On Oct 25, 2023, Celltrion reported US FDA approval of Zymfentra (infliximab) for continued treatment of adult ulcerative colitis (UC) and Crohn's disease (CD) after intravenous infliximab treatment.